


Developmental Cell

DUX4 Suppresses MHC Class I to Promote Cancer Immune Evasion and Resistance to Checkpoint Blockade

Graphical Abstract



Authors

Guo-Liang Chew, Amy E. Campbell, Emma De Neef, Nicholas A. Sutliff, Sean C. Shadle, Stephen J. Tapscott, Robert K. Bradley

Correspondence

stapscot@fredhutch.org (S.J.T.), rbradley@fredhutch.org (R.K.B.)

In Brief

Chew and Campbell et al. report that DUX4, a preimplantation embryonic transcription factor that is normally silenced in somatic tissues, is re-expressed in many cancers. DUX4 suppresses anti-cancer immune activity by blocking interferon- γ -mediated induction of MHC class I and is associated with reduced efficacy of immune checkpoint blockade therapy.

Highlights

- The early embryonic transcription factor DUX4 is active in many human cancers
- *DUX4*-expressing cancers are characterized by low anti-tumor immune activity
- DUX4 blocks interferon- γ -mediated induction of MHC class I and antigen presentation
- DUX4 is significantly associated with failure to respond to anti-CTLA-4 therapy

DUX4 Suppresses MHC Class I to Promote Cancer Immune Evasion and Resistance to Checkpoint Blockade

Guo-Liang Chew,^{1,2,7} Amy E. Campbell,^{3,7} Emma De Neef,^{1,2,4} Nicholas A. Sutliff,^{3,5} Sean C. Shadle,^{3,5} Stephen J. Tapscott,^{3,6,*} and Robert K. Bradley^{1,2,4,8,*}

¹Computational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA

²Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA

³Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA

⁴Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA

⁵Molecular and Cellular Biology Program, University of Washington, Seattle, WA 98195, USA

⁶Department of Neurology, University of Washington, Seattle, WA 98195, USA

⁷These authors contributed equally

⁸Lead Contact

*Correspondence: stapscot@fredhutch.org (S.J.T.), rbradley@fredhutch.org (R.K.B.)

<https://doi.org/10.1016/j.devcel.2019.06.011>

SUMMARY

Advances in cancer immunotherapies make it critical to identify genes that modulate antigen presentation and tumor-immune interactions. We report that DUX4, an early embryonic transcription factor that is normally silenced in somatic tissues, is re-expressed in diverse solid cancers. Both *cis*-acting inherited genetic variation and somatically acquired mutations in *trans*-acting repressors contribute to DUX4 re-expression in cancer. Although many DUX4 target genes encode self-antigens, DUX4-expressing cancers were paradoxically characterized by reduced markers of anti-tumor cytolytic activity and lower major histocompatibility complex (MHC) class I gene expression. We demonstrate that DUX4 expression blocks interferon- γ -mediated induction of MHC class I, implicating suppressed antigen presentation in DUX4-mediated immune evasion. Clinical data in metastatic melanoma confirmed that DUX4 expression was associated with significantly reduced progression-free and overall survival in response to anti-CTLA-4. Our results demonstrate that cancers can escape immune surveillance by reactivating a normal developmental pathway and identify a therapeutically relevant mechanism of cell-intrinsic immune evasion.

INTRODUCTION

Immune checkpoint blockade therapies, which act on T cell inhibitory receptors including CTLA-4 and PD-1, induce durable responses across diverse cancers. However, a majority of patients do not respond to these therapies, and initially responsive cancers may relapse (Ribas and Wolchok, 2018; Sharma et al.,

2017; Topalian et al., 2015). Identifying molecular mechanisms that influence therapeutic response and relapse is critical in order to realize the full therapeutic potential of checkpoint blockade.

The efficacy of checkpoint blockade relies upon cytotoxic T cell recognition of antigens presented by MHC class I on malignant cells. As a consequence, genetic lesions that suppress antigen presentation or blunt tumor-immune interactions can permit malignant cells to evade cytotoxic T cells. For example, loss-of-function mutations in *B2M*, *JAK1*, and *JAK2*, resulting in loss of major histocompatibility complex (MHC) class I expression (*B2M*) or response to interferon- γ (*JAK1* and *JAK2*), have been identified in patients who relapsed following an initial response to checkpoint blockade (Sade-Feldman et al., 2017; Zaretsky et al., 2016). Copy number alterations affecting MHC class I and interferon- γ -response genes are likewise enriched in cancers that never respond to these therapies (Gao et al., 2016; Sade-Feldman et al., 2017). Tumors can also evade immune recognition by activating specific gene expression programs. For example, activation of β -catenin signaling promotes T cell exclusion from the melanoma microenvironment (Spranger et al., 2015), while depletion of LSD1 promotes anti-tumor immune activity (Sheng et al., 2018). Other modulators of tumor-immune interactions continue to be revealed by genetic screens and other methods (Manguso et al., 2017; Pan et al., 2018; Patel et al., 2017).

We performed a pan-cancer analysis of tumor transcriptomes in order to identify potential regulators of tumor-immune interactions. We sought to identify genes whose expression was restricted to cancers or immune-privileged sites such as the testes and early embryo. While such approaches have been historically used to identify cancer-testis (CT) antigens—proteins whose expression is normally restricted to the embryo and/or germ cells but which can become re-expressed and antigenic in cancer (Caballero and Chen, 2009)—we hypothesized that such a search might also reveal regulators of antigen presentation and immune modulation. We therefore undertook an unbiased search for such genes using the transcriptomes of 9,759 samples from 33 distinct cancer types, 704 associated




Figure 1. Identification of Genes with Cancer-Specific Expression

(A) Overview of data sources and our strategy for identifying cancer-specific gene expression. We compared the expression of each gene in cancer samples (TCGA) to its corresponding expression in peritumoral samples (TCGA) and normal tissue from healthy individuals (Illumina Body Map 2.0, Human Proteome Map, and Genotype-Tissue Expression Project, GTEx). We defined the cancer specificity score for each gene as the logarithm of the fractions of cancer samples and types in which the gene was expressed divided by the fractions of peritumoral samples and normal tissues in which the gene was expressed.

(B) Ranked plot of cancer specificity scores of coding genes, restricted to genes that are not expressed in all tissue types. The double homeobox genes *DUX4*, *DUXA*, and *DUXB* are highlighted.

(C) Expression of cancer-specific genes across cancer types and samples. Each point corresponds to a gene highlighted in red in (B). y axis, number of cancer types (TCGA primary site) with at least one DUX4+ sample; x axis, total number of DUX4+ samples, irrespective of cancer type.

(D) DUX4 mRNA levels in DUX4+ cancer samples and during early embryogenesis (Hendrickson et al., 2017). TPM, transcripts per million.

See also Figure S1.

peritumoral normal samples, and 34 tissues from healthy individuals. Our analysis revealed that *DUX4*, an early embryonic transcription factor that is normally silenced in somatic tissues, is re-expressed in many solid cancer types. *DUX4* re-expression in cancer results in suppression of MHC class I-dependent antigen presentation, immune evasion, and resistance to immune checkpoint blockade.

RESULTS

Large-Scale Identification of Genes with Cancer-Specific Expression Patterns

We sought to identify genes that were expressed in multiple cancer types but not in corresponding peritumoral normal tissues or other somatic tissues isolated from healthy individuals. We compared the transcriptomes of 9,759 cancer samples from 33 distinct cancers (The Cancer Genome Atlas, TCGA) to the transcriptomes of 34 normal tissues, including peritumoral normal tissues (TCGA) and somatic tissues of healthy individuals (Illumina Human Body Map 2.0, GTEx, and Human Proteome Map) (Kim et al., 2014; Kosti et al., 2016). We computed a quantitative measure of cancer-specific expression for each gene that was pro-

portional to the numbers of cancer samples and types in which the gene was expressed and inversely proportional to the numbers of peritumoral normal samples and other healthy somatic tissues exhibiting detectable expression of the gene (Figure 1A).

Our quantitative cancer-specific expression score allowed us to rank each gene according to its relative level of expression in malignant versus normal somatic tissue (Figures 1B and S1A; Table S1). Our analysis highlighted many genes with known roles in tumorigenesis, including *OCT4* pseudogenes (Hayashi et al., 2015) and genes that are recurrently translocated in cancer, such as *TLX3* and members of the *SSX* gene family (Smith and McNeel, 2010). Many genes that exhibited the most cancer-specific expression patterns encode known CT antigens, including members of the *GAGE*, *MAGE*, *PAGE*, *PRAME*, and *SPANX* gene families.

Given that CT antigens were strongly enriched among the most cancer-specific genes, we tested whether other classes of genes were preferentially expressed in cancers. We performed a Gene Ontology (GO)-based comparison of the 500 highest-scoring genes against a background set of non-ubiquitously expressed genes. We used non-ubiquitously expressed

genes as a background set in order to avoid confounding our analysis with housekeeping genes. Genes involved in spermatogenesis comprised $\sim 5\%$ of the most cancer-specific genes (false discovery rate [FDR] $< 10^{-3}$), consistent with our identification of many CT antigens. Unexpectedly, the most enriched biological pathway was transcriptional regulation (FDR $< 10^{-5}$), which encompassed 19% of the highest-ranked genes. 28 of the 500 highest ranked genes encode sequence-specific transcription factors, many of which are normally expressed only in germ cells or the embryo. Each of these factors could potentially influence tumor-immune interactions by modulating CT antigen expression, antigen presentation, or interferon signaling.

DUX4 Is Re-expressed in Diverse Cancers

Three genes (*CGB5*, *SMC1B*, and *DUX4*) exhibited the strongest pan-cancer signals. Expressed in testes but not in any queried somatic tissues, they were each also expressed in solid cancers arising from 26 distinct tissue types (Figures 1B, 1C, and S1B). *SMC1B* encodes a meiosis-specific subunit of cohesin (Revenkova et al., 2001); *CGB5* encodes a subunit of chorionic gonadotropin; *DUX4* encodes an early embryonic transcription factor (De Iaco et al., 2017; Hendrickson et al., 2017; Snider et al., 2010; Whiddon et al., 2017). Chorionic gonadotropin promotes maternal immunotolerance and is a biomarker of cancer (Kayisli et al., 2003; Stenman et al., 2004), suggesting that our ranking of cancer-specific genes enriched for potential mediators of tumor-immune interactions.

DUX4 was a particularly intriguing candidate for modulating tumor-immune interactions. *DUX4* encodes a double homeobox transcription factor that acts as a pioneer factor demarcating the two-cell “cleavage” stage of early embryogenesis, after which it is epigenetically repressed (De Iaco et al., 2017; Hendrickson et al., 2017; Snider et al., 2010; Whiddon et al., 2017). *DUX4* is expressed at low levels in the immune-privileged sites of the testis and thymus but otherwise silenced in somatic tissues (Das and Chadwick, 2016; Snider et al., 2010). Several genes that are direct transcriptional targets of *DUX4*, such as *PRAME* genes, encode CT antigens that were first identified based on their cancer-specific expression and immunogenic potential (Chang et al., 2011; Ikeda et al., 1997). *DUX4* was commonly expressed in cancers of the bladder, breast, cervix, endometrium, esophagus, lung, ovary, kidney, soft tissue, and stomach, and particularly frequently expressed in testicular germ cell cancers and thymomas (Figure 1D).

DUX4 Is Expressed at Physiological Levels as a Full-Length mRNA

Since *DUX4* is normally silenced in somatic cells, we first tested whether *DUX4* was expressed at potentially physiologically relevant levels. We compared *DUX4* mRNA levels in *DUX4*-expressing (*DUX4*+) cancer samples to *DUX4* mRNA levels during early embryogenesis, including the cleavage stage, whose transcriptional program is driven by *DUX4*. *DUX4* was typically expressed at levels ranging from ~ 2 –10 transcripts per million (TPM) in *DUX4*+ cancer samples, comparable to its endogenous expression during embryogenesis (Figure 1D).

We next confirmed that cancers expressed a full-length transcript encoding the complete *DUX4* transcription factor. Testing for full-length *DUX4* mRNA expression was important for three

reasons. First, alternative splicing generates multiple *DUX4* isoforms, of which only the longest isoform includes the *DUX4* C-terminal transcription activation domain (Geng et al., 2012; Snider et al., 2010). Second, *DUX4* is recurrently translocated in round-cell sarcoma and B cell acute lymphoblastic leukemia (B-ALL) to the *CIC* and *IGH* loci, generating fusion proteins containing N- and C-terminal truncations of *DUX4*, respectively (Kawamura-Saito et al., 2006; Lilljebjörn et al., 2016; Liu et al., 2016; Yasuda et al., 2016; Zhang et al., 2016). Because *DUX4* requires both its N-terminal DNA-binding domains and its C-terminal activation domain to activate its target genes (Choi et al., 2016), neither fusion protein preserves endogenous *DUX4* function. Third, *DUX4* exhibits high sequence homology to its paralog *DUX4C*, such that errors in short-read alignment could potentially confound estimates of *DUX4* versus *DUX4C* mRNA levels.

We assessed *DUX4* alternative splicing by testing whether the long or short isoform of *DUX4* was preferentially expressed in cancers. We identified spliced reads that unambiguously distinguished between the two isoforms in approximately one-third of *DUX4*+ samples. Only four *DUX4*+ samples exhibited any evidence of short isoform expression, and in each case, we observed only one or two reads supporting the short isoform (data not shown). The vast majority of expressed *DUX4* mRNA arose from the long isoform containing the complete open reading frame.

We next tested whether *DUX4* was expressed in solid cancers as a full-length *DUX4* mRNA, or instead as a truncated *DUX4* mRNA consisting of the 5' end of the *DUX4* mRNA fused to another gene product (as occurs in B-ALL). We aligned reads from each *DUX4*+ solid cancer, preimplantation embryos, and B-ALL with *DUX4* translocations to the full-length *DUX4* mRNA sequence. Read coverage extended across the full-length *DUX4* mRNA in preimplantation embryos, as expected, as well as in all *DUX4*+ solid cancers (Figures 2A–2C). In contrast, reads aligned only to the 5'-most half of the *DUX4* mRNA in B-ALL, consistent with the known presence of *DUX4* translocations in these leukemias (Figure 2D). We did not observe read coverage patterns consistent with expression of a fusion gene encoding an N- or C-terminally truncated fragment of *DUX4* in any *DUX4*+ solid cancer (Figures S2A and S2B).

Finally, we tested whether mis-alignment of reads from *DUX4C* to *DUX4* was a confounding factor in our analysis. The *DUX4C* and *DUX4* open reading frames are highly similar, with the exception of 32 residues at *DUX4C*'s C terminus. Identifying reads that mapped uniquely to the distinguishing regions of *DUX4C* and *DUX4* revealed that while a few *DUX4*+ samples also exhibited detectable *DUX4C* expression, the vast majority of mapping reads aligned uniquely to *DUX4* (Figure S2C). Together with our analyses of *DUX4* splicing and read coverage patterns, these data indicate that *DUX4*+ solid cancers express full-length *DUX4* mRNA.

Genetic Variation and Somatic Mutations Contribute to DUX4 Expression in Cancer

Normally silenced in somatic cells, *DUX4* becomes inappropriately re-expressed in the skeletal muscle of individuals with facioscapulohumeral muscular dystrophy (FSHD) due to *cis*- and/or *trans*-acting genetic variation that disrupts normal epigenetic repression of the *DUX4* locus (Lemmers et al., 2012, 2010). We




Figure 2. DUX4 Is Expressed as a Full-Length mRNA in Diverse Solid Cancers

(A) Schematic of *DUX4* isoform that encodes the full-length transcription factor. Red, sequence encoding the DNA-binding homeodomains (HB1 and HB2); yellow, sequence encoding the C-terminal activation domain.

(B) Read coverage of the *DUX4* isoform illustrated in (A) in embryos (Hendrickson et al., 2017). Gray shaded box, open reading frame. Plot based on image from IGV.

(C) As (B), but for representative *DUX4*+ solid cancers.

(D) As (B), but for B-ALL with *DUX4-IGH* translocations.

(E) Numbers of RNA-seq reads aligning to the polyadenylation signal in *DUX4*'s third exon (Exon 3 PAS). Each point is a single *DUX4*+ sample, whose genotype was inferred by mapping reads to diagnostic polymorphisms corresponding to the "permissive" 4qA161 or a "non-permissive" (10qA or 4qB) alleles in *DUX4*'s second exon. The analyzed data are from poly(A)-selected libraries. ***p < 0.001 by the one-sided Mann-Whitney U test.

(F) *DUX4* mRNA levels (TPM) in samples from testicular germ cell tumors, segregated by *DPPA2* and *DPPA4* expression. <25th and >75th indicate the bottom and top quartiles. ***p < 0.001; ****p < 0.0001 by the one-sided Mann-Whitney U test. Error bars, standard deviations estimated by bootstrapping. TPM, transcripts per million.

(G) Association between predicted loss-of-function mutations affecting known or likely repressors of *DUX4* expression with increased *DUX4* mRNA levels. Colors indicate p-values computed with a one-sided Mann-Whitney U test. See also Figure S2D.

(H) qRT-PCR measurement of *PRPF8*, *DUX4*, *ZSCAN4*, and *TRIM43* mRNA levels following transfection of a pool of four *PRPF8*-targeting siRNAs or a control non-targeting siRNA into myoblasts isolated from a healthy (MB2401) or FSHD (MB073) individual. The FSHD myoblasts have a permissive genetic background that potentiates *DUX4* expression. Error bars, standard deviation across biological replicates. See also Figure S2.

hypothesized that similar mechanisms might contribute to *DUX4* expression in cancers. We first used reads mapping to the 3' end of the *DUX4* mRNA to assess whether the *DUX4* mRNA was expressed from a "permissive" 4qA161 allele or a "non-permissive" (10qA or 4qB) allele, which respectively do or do not contain consensus polyadenylation sites that permit stable *DUX4* mRNA expression (Lemmers et al., 2010, 2007). We observed significantly more reads arising from permissive alleles (Figure 2E; p < 0.001), indicating that inherited genetic variation contributes to *DUX4* expression in cancer as well as FSHD.

We next identified *trans*-acting regulators of *DUX4* expression in cancer. Two recent studies reported that *DPPA2* and *DPPA4* activate expression of *Dux*, a murine double homeobox gene that is expressed during early embryogenesis like *DUX4* (De Iaco et al., 2019; Eckersley-Maslin et al., 2019). Although mice

lack *DUX4* and the relationship between human *DPPA2* and *DPPA4* and *DUX4* has not been tested, we wondered whether the same occurred in cancers. High *DPPA2* and *DPPA4* expression was strongly associated with *DUX4* expression in testicular germ cell tumors but no other cancer types, suggesting that human *DPPA2* and *DPPA4* may activate *DUX4* expression in some cell types (Figure 2F). We next tested whether somatic mutations affecting known repressors of the *DUX4* locus were associated with *DUX4* expression. We identified all cancer samples with or without predicted loss-of-function mutations in 23 genes encoding validated or likely repressors of *DUX4*, including proteins encoded by Modifier of murine metastable epiallele (Mome) genes (Daxinger et al., 2013), components of the nucleosome remodeling deacetylase and chromatin assembly factor 1 complexes (Campbell et al., 2018), and other epigenetic

factors (Haynes et al., 2018; Huichalaf et al., 2014; Ottaviani et al., 2009; Zeng et al., 2009) (Table S2). We tested whether samples with loss-of-function mutations in each gene exhibited elevated *DUX4* expression relative to wild-type samples for each cancer type. Mutations in 12 tested genes were significantly associated with increased *DUX4* expression in one or more cancer types (Figures 2G and S2D), suggesting that loss of epigenetic repressors of the *DUX4* locus contributes to *DUX4* re-expression in cancer.

One of the strongest signals in our mutational analysis arose from *PRPF8*, which encodes a core spliceosomal protein. Although *PRPF8* is not a known repressor of *DUX4*, we included *PRPF8* in our analysis because we previously found that *PRPF8* physically associates with the *DUX4* locus (Campbell et al., 2018). We therefore experimentally tested whether *PRPF8* inhibition induced *DUX4* expression. We knocked down (KD) *PRPF8* in myoblasts isolated from a healthy individual and an individual whose FSHD was caused by *cis*-acting genetic variation that potentiated *DUX4* de-repression. *PRPF8* KD resulted in increased *DUX4* expression and upregulation of the *DUX4* targets *ZSCAN4* and *TRIM43*, confirming the presence of transcriptionally active *DUX4* protein following *PRPF8* KD (Figure 2H). The extent of upregulation was much higher in FSHD cells, as expected. In addition to identifying *PRPF8* as a repressor of *DUX4* expression, our results demonstrate that both *cis*-acting genetic variation and somatic mutations in *trans*-acting repressors contribute to *DUX4* expression in cancer.

DUX4 Drives an Early Embryonic Gene Expression Program in Cancer

We next tested whether *DUX4* mRNA was likely translated into a functional transcription factor in *DUX4*+ cancers. As a pioneer transcription factor, *DUX4* induces a stereotyped cleavage-stage gene expression program, even when it is aberrantly expressed in somatic cells outside of its normal embryonic context (Figure 3A). *DUX4* also binds to and transcriptionally activates specific repetitive elements (Geng et al., 2012; Young et al., 2013), many of which characterize the cleavage-stage gene expression program (Hendrickson et al., 2017). We computed a high-confidence set of *DUX4*-induced target genes by intersecting the sets of genes associated with endogenous *DUX4* expression during preimplantation embryogenesis as well as ectopic *DUX4* expression in induced pluripotent stem cells (iPSCs) and myoblasts (Feng et al., 2015; Hendrickson et al., 2017). We additionally defined a compact set of *DUX4*-responsive repetitive elements that were induced irrespective of the cell type (Table S3). We measured expression levels of each of these *DUX4*-induced genes and repetitive elements across each cancer cohort and compared their average expression in *DUX4*+ versus *DUX4*– cancers.

DUX4 expression was strongly associated with increased expression of *DUX4* targets, including coding genes, non-coding genes, and repetitive elements (Figure 3B). Several trends were notable. First, while *DUX4*+ cancers exhibited increased expression of many *DUX4*-induced genes irrespective of cancer type, one or more specific target genes were particularly highly expressed in each cancer type. For example, almost all *DUX4*+ thymomas expressed high levels of the *DUX4* target *CCNA1*, while few bladder or breast cancers did. Second, the quantitative

level of *DUX4* target induction was highly variable across *DUX4*+ cancer samples and was only modestly correlated with *DUX4* expression levels. Third, most *DUX4* targets were strongly induced in almost all *DUX4*+ testicular germ cell cancers. Testicular germ cell cancers might constitute unusually permissive environments for *DUX4* activity, perhaps because *DUX4* is endogenously expressed in luminal cells in the testis, most likely in the germline (Snider et al., 2010). We conclude that *DUX4* drives an early embryonic transcriptional program in diverse solid cancers.

DUXB Is Not Essential for the Core DUX4 Transcriptional Program in Cancer

A recent study reported that *Duxbl* was recurrently amplified in a murine model of rhabdomyosarcoma and that its human ortholog *DUXB* was expressed in many human cancers (Preussner et al., 2018). Although we also observed frequent *DUXB* expression in cancers, *DUXB* did not rank highly on our cancer specificity index because it is expressed in many healthy tissues (Figure 1B). Nonetheless, as *DUXB* expression is promoted by *DUX4* (Figures 3A and 3B), we wondered whether *DUXB* might contribute to the *DUX4*-induced gene expression program. We established a myoblast cell line with a doxycycline-inducible *DUXB* transgene and performed RNA-seq on cells with or without doxycycline treatment. Although *DUXB* lacks *DUX4*'s C-terminal transcriptional activation domain, *DUXB* induction resulted in statistically significant upregulation of a small set of genes. However, *DUXB* had no effects on our high-confidence set of *DUX4* targets (Figures S3B and S3C; Table S4), suggesting that it is not essential for the *DUX4*-driven embryonic expression program in cancer.

DUX4 Is Associated with Reduced Anti-tumor Immune Activity

As many *DUX4* targets encode CT antigens (Chang et al., 2011; Ikeda et al., 1997), we wondered whether *DUX4* re-expression might promote anti-tumor immune activity. We therefore tested whether *DUX4*-expressing cancers exhibited gene expression signatures of high immune infiltration. To our surprise, multiple lines of evidence indicated that *DUX4* expression was associated with decreased, rather than increased, anti-tumor immune activity. First, we identified genes that were consistently differentially expressed in multiple cancer types in *DUX4*+ versus *DUX4*– samples and performed a GO-based analysis of enriched functional categories (Figure S3A). Almost all enriched GO terms belonged to immune-related categories. However, contrary to our hypothesis that *DUX4* expression might trigger immune surveillance, the immune-related GO terms were uniformly associated with decreased gene expression in *DUX4*+ versus *DUX4*– cancers (Figure 4A). Second, we noticed that many immune-cell-specific genes were down-regulated in *DUX4*+ cancers, suggesting that reduced immune cell infiltration might underlie this GO enrichment signature (Table S5). We therefore estimated infiltration of different immune cell types in *DUX4*+ and *DUX4*– cancers with the TIMER algorithm (Li et al., 2017). *DUX4* expression was associated with reduced infiltration of diverse immune cells, most notably cytotoxic CD8+ T cells, in many cancers (Figures 4B, S4A, and S4B). Natural killer (NK) cell-specific markers exhibited similarly reduced expression in many *DUX4*+ cancer types (Figure S4C). Third, we estimated anti-tumor immune activity by measuring the expression of




Figure 3. DUX4 Drives an Embryonic Gene Expression Program in Cancer

(A) Differential gene expression induced by endogenous or ectopic DUX4. Each point represents mRNA levels for a single gene in samples with (y axis) or without (x axis) *DUX4* expression. Plots illustrate comparisons between cleavage-stage embryos and zygotes, which have high and low *DUX4* expression (left panel), iPSCs with or without *DUX4* induction (center panel), and myoblasts with or without *DUX4* induction (right panel) (Feng et al., 2015; Hendrickson et al., 2017). Red, high-confidence list of DUX4-induced genes identified by intersecting the sets of upregulated genes in all three illustrated comparisons. TPM, transcripts per million. (B) Expression of high-confidence DUX4 targets in DUX4+ cancers. Heat map illustrates the expression of each DUX4 target (rows) in each individual DUX4+ sample (columns) relative to the median expression across all DUX4- samples from that cancer type. The LSAU repetitive element corresponds to the beta satellite repeat, which is a multicopy genomic element like DUX4. Approximately 55% of LSAU's 2,759-nt consensus sequence overlaps with part of DUX4's consensus sequence, so its expression is invariably higher in DUX4+ samples when expression is quantified via short-read sequencing. See also Figure S3.

GZMA and *PRF1*, which encode two key cytolytic factors expressed by cytotoxic T cells and NK cells (Rooney et al., 2015), to find that cytolytic activity was markedly lower in most DUX4+ versus DUX4- cancers (Figures 4C and S4D).

As immunosuppressive regulatory T cells (Tregs) play important roles in tolerance of self-antigens (Sakaguchi et al., 2008), we wondered whether DUX4 might create an immunosuppressive environment by altering Treg recruitment. The Treg marker




Figure 4. DUX4 Is Associated with Cancer Immune Evasion

(A) Gene Ontology (GO) terms that were enriched for genes that were differentially expressed in DUX4+ versus DUX4- samples across multiple cancer types. Plot is restricted to the child-most GO terms with a false discovery rate (FDR) ≤ 0.01 after Benjamini-Hochberg correction. Circle areas are proportional to $-\log_{10}$ (FDR).

(B) Estimated CD8⁺ T cell infiltration in DUX4- and DUX4+ cancers, where infiltration was estimated with the TIMER method (Li et al., 2017). * $p < 0.05$; ** $p < 0.01$ by the one-sided Mann-Whitney U test.

(C) Mean estimated cytolysis activity in DUX4- and DUX4+ cancers. Cytolytic activity was estimated as the geometric mean of *GZMA* and *PRF1* gene expression (Rooney et al., 2015). Error bars, standard deviations estimated by bootstrapping.

(D) Mean expression of canonical MHC class I genes, where the mean was computed over all DUX4- and DUX4+ cancers for each type. Error bars, standard deviations estimated by bootstrapping. TPM, transcripts per million.

(E) As (D), but for the illustrated datasets. Feng et al. (2015) introduced DUX4 via lentivirus into 54-1 and MB135 myoblasts (Feng et al., 2015), Rickard et al. (2015) sorted DUX4- and DUX4+ myoblasts following induction of differentiation for myoblasts that spontaneously express DUX4 (Rickard et al., 2015), and Eidahl et al. (2016) transfected DUX4-expressing plasmids into WS236 myoblasts (Eidahl et al., 2016). n, number of replicates.

See also Figure S4.

gene *FOXP3* was significantly down-regulated in DUX4+ samples in a few, although not most, cancer types (Figure S4E). However, this association did not persist when we estimated Treg infiltration with the more sophisticated CIBERSORT algorithm (Newman et al., 2015; Thorsson et al., 2018) (Figure S4F), suggesting that DUX4-mediated immunosuppression is likely not explained by Treg recruitment.

DUX4 Suppresses MHC Class I Expression

As DUX4 promotes CT antigen expression yet DUX4+ cancers exhibited low anti-tumor immune activity, we wondered whether antigen presentation might be suppressed in DUX4-expressing cells. Reduced expression or loss of the Human Leukocyte Antigen (*HLA*) or *B2M* ($\beta 2$ microglobulin) genes, which encode MHC class I molecules that display peptides for immune recognition, is a common mechanism by which cancers evade immune surveil-

lance (Shukla et al., 2015). We therefore compared the expression levels of MHC class I genes in DUX4+ and DUX4- cancers to find that DUX4 expression was associated with reduced expression of *B2M*, *HLA-A*, *HLA-B*, and *HLA-C* in most cancer types (Figure 4D).

Decreased expression of MHC class I genes could be a direct consequence of DUX4 expression or alternatively might be an independent event that enhances the survival of DUX4-expressing cancers. For example, cancers that evade immune surveillance might be under reduced immune selection, enabling them to subsequently express DUX4 and its antigenic targets without deleterious consequences. To distinguish between those possibilities, we studied acute DUX4 expression in cell culture. We re-analyzed two RNA-seq datasets in which DUX4 was ectopically expressed in DUX4- cells (Eidahl et al., 2016; Feng et al., 2015) and one dataset in which differentiating myoblasts that spontaneously expressed DUX4 were flow-sorted into




Figure 5. DUX4 Blocks Interferon- γ -Mediated Upregulation of MHC Class I-Dependent Antigen Presentation

(A) Mean expression of genes encoding the illustrated components of the interferon- γ signaling pathway, where the mean was computed over all DUX4- and DUX4+ cancers for each type. Error bars, standard deviations estimated by bootstrapping. TPM, transcripts per million.

(B) As (A), but for the illustrated datasets.

(C) As (A), but illustrating gene expression during preimplantation embryonic development.

(D) Immunoblots probing MHC class I, DUX4, and GAPDH protein following treatment of MB135 cells that were engineered to contain a doxycycline-inducible DUX4 expression construct with interferon- γ (IFN- γ) and/or doxycycline (Dox) to induce DUX4. α -MHC I, pan-MHC class I probe.

(E) As (D), but for MCF-7 cells.

(F) As (D), but for HeLa cells.

(G) As (D), but for Mel375 and Mel526 cells.

(H) As (D), but for A204 cells.

(I) As (D), but for SuSa cells.

(J) Levels of MHC class I on the cell surface following treatment of MB135iDUX4 cells with interferon- γ (IFN- γ) and/or doxycycline (Dox) to induce DUX4. Cell surface levels of MHC class I were probed with a pan-MHC class I antibody.

(K) As (J), but for HeLa iDUX4 cells.

See also Figure S5.

DUX4+ and DUX4- pools (Rickard et al., 2015). We found that DUX4-expressing cells exhibited reduced levels of MHC class I genes relative to DUX4- control cells in all three datasets (Figure 4E). As immunoeediting is not a potential confounding factor in these cell culture experiments, we conclude that DUX4 is a cell-intrinsic suppressor of MHC class I.

DUX4 Suppresses Interferon- γ -Mediated Induction of MHC Class I-Dependent Antigen Presentation

Tumor-infiltrating immune cells induce antigen presentation on malignant cells by secreting interferon- γ , resulting in the upregulation of MHC class I genes via JAK1-, JAK2-, and STAT1-

dependent signal transduction (Friedman et al., 1984; Schroder et al., 2004). We noted that DUX4 expression was associated with reduced expression of JAK1, JAK2, and/or STAT1 in many cancer types (Figure 5A). JAK1, JAK2, and STAT1 exhibited similarly reduced expression following acute DUX4 expression in cultured myoblasts (Figure 5B) as well as after the onset of endogenous DUX4 expression in preimplantation embryos (Figure 5C). Finally, we noted that JAK1, JAK2, and STAT1 each exhibited multiple peaks of DUX4 binding in our published chromatin immunoprecipitation sequencing (ChIP-seq) dataset of acute DUX4 expression in cultured myoblasts (Figure S5A) (Geng et al., 2012).




Figure 6. DUX4 Expression Is Associated with Resistance to Immune Checkpoint Blockade

(A) Fractions of DUX4 target genes (Table S3) that are expressed in pretreatment biopsies taken from metastatic melanoma patients who received anti-CTLA-4 (Van Allen et al., 2015) or anti-PD-1 (Hugo et al., 2016) therapy. Clinical responses were classified in the original studies according to RECIST (anti-CTLA-4) (Eisenhauer et al., 2009) or irRECIST (anti-PD-1) (Wolchok et al., 2009). p-value computed with the Wilcoxon rank-sum test. (B) Progression-free survival for patients treated with anti-CTLA-4 whose pretreatment biopsies fell within the top or bottom terciles of DUX4 target gene expression. p-value computed with the log-rank test. (C) As (B), but for overall survival. (D) As (B), but for the cohort of patients treated with anti-PD-1.

We therefore tested whether DUX4 could block interferon- γ -mediated induction of MHC class I. We initially used MB135iDUX4 cells, which permit doxycycline-inducible DUX4 expression in a myoblast cell line. MB135iDUX4 cells are a validated model of the biological consequences of DUX4 expression that recapitulate the cleavage-stage transcriptional program (Hendrickson et al., 2017; Jagannathan et al., 2016; Whiddon et al., 2017). Treatment with interferon- γ resulted in robust upregulation of MHC class I protein, as expected, while inducing DUX4 by adding doxycycline effectively blocked this upregulation of MHC class I (Figure 5D). DUX4 induction drove expression of the DUX4-activated embryonic gene ZSCAN4 independent of interferon- γ treatment while suppressing interferon- γ -mediated upregulation of B2M, HLA-A, HLA-B, and HLA-C mRNA (Figures S5B and S5C). Adding doxycycline in the absence of the inducible DUX4 construct had no effect on interferon- γ -mediated induction of MHC class I (Figure S5D).

We next tested whether DUX4 blocked interferon- γ -mediated induction of MHC class I protein in cancer cells. We introduced a doxycycline-inducible DUX4 construct into six cell lines derived from five cancer types: breast adenocarcinoma (MCF-7), cervical cancer (HeLa), melanoma (Mel375 and Mel526), rhabdoid cancer (A204), and testicular teratocarcinoma (SuSa). Treatment with interferon- γ induced higher levels of MHC class I protein in all tested cell lines, and DUX4 suppressed this induction (Figures 5E–5I). Treating the parental cell lines with doxycycline

had no effect on interferon- γ -mediated induction of MHC class I (Figure S5D).

Finally, we confirmed that DUX4 blocked interferon- γ -mediated induction of MHC class I-dependent antigen presentation. As peptide binding is required for MHC class I stability and cell surface localization (Townsend et al., 1989), we used flow cytometry to measure how DUX4 affected levels of MHC class I on the cell surfaces of representative untransformed (MB135) and cancer (HeLa) cell lines. Interferon- γ

treatment drove robust upregulation of MHC class I on the cell surface, as expected, while DUX4 abrogated this induction in both cell types (Figures 5J, 5K, S5E, and S5F). DUX4-mediated suppression of MHC class I was particularly notable in HeLa cells, where DUX4 suppressed cell surface levels of MHC class I beyond the basal state even in the presence of interferon- γ . Together, these data demonstrate that DUX4 blocks interferon- γ -mediated induction of MHC class I and antigen presentation in untransformed and cancer cells.

DUX4 Promotes Resistance to Immune Checkpoint Blockade

As immune checkpoint blockade relies upon antigen presentation, resistance to these therapies is strongly associated with loss of antigen presentation as well as loss of interferon- γ signal transduction (Gao et al., 2016; Sade-Feldman et al., 2017; Zaretsky et al., 2016). We therefore hypothesized that DUX4-mediated suppression of antigen presentation might promote resistance to checkpoint blockade. We analyzed RNA-seq data from pretreatment biopsies across two cohorts in which patients with metastatic melanoma were treated with anti-CTLA-4 (Van Allen et al., 2015) or anti-PD-1 (Hugo et al., 2016). Biopsies from patients whose disease was clinically classified as non-responsive to anti-CTLA-4 exhibited significantly higher levels of DUX4 transcriptional activity relative to biopsies from responsive patients (Figure 6A). Stratifying patients according to DUX4 transcriptional activity revealed dramatic and

statistically significant differences in both progression-free and overall survival following anti-CTLA-4 therapy (Figures 6B and 6C). Increased DUX4 transcriptional activity was similarly associated with failure to respond to anti-PD-1 therapy (Figure 6A) and decreased overall survival following anti-PD-1 treatment (Figure 6D), although the differences were not statistically significant, perhaps because of the smaller size of the anti-PD-1 cohort (27 versus 41 patients) or a more predictive role for MHC class I expression in response to anti-CTLA-4 than anti-PD-1 therapy (Rodig et al., 2018). We conclude that DUX4-mediated suppression of MHC class I-dependent antigen presentation is a clinically relevant biomarker for response to immune checkpoint blockade.

DISCUSSION

Our finding of *DUX4* expression in diverse solid cancers was notable for several reasons. First, as *DUX4* acts as a pioneer transcription factor that contributes to zygotic genome activation, *DUX4* re-expression in cancer provides a functional link between early embryogenesis and cancer (De Iaco et al., 2017; Hendrickson et al., 2017; Whiddon et al., 2017). Second, prior to the recent discovery of *DUX4*'s embryonic role, *DUX4* was best known for causing FSHD when aberrantly expressed in skeletal muscle due to genetic variation that causes loss of its normal epigenetic repression in somatic tissues (Lemmers et al., 2010, 2012). Third, while *DUX4*'s normal transcription factor activity has not been previously reported to play a role in cancer, the presence of recurrent translocations involving the *DUX4* locus in round-cell sarcoma and B-ALL strongly suggests that *DUX4* has pro-oncogenic capacity, at least when expressed as part of the CIC-DUX4 or DUX4-IGH fusion proteins (Kawamura-Saito et al., 2006; Lilljebjörn et al., 2016; Liu et al., 2016; Yasuda et al., 2016; Zhang et al., 2016). Finally, our observation that *DUX4* activity is significantly associated with failure to respond to immune checkpoint blockade (Figure 6) provides a clinical motivation for determining when, where, and how *DUX4* becomes re-expressed in cancers. Future prospective studies of larger cohorts are essential to confirm our results and test the clinical utility of using *DUX4* activity as a predictive biomarker of response to checkpoint blockade.

DUX4 is aberrantly expressed in both FSHD muscle and cancers, but the physiological consequences of *DUX4* expression in these two disease states are quite different. Sustained expression of *DUX4* in skeletal muscle causes apoptosis (Eidahl et al., 2016; Kowalijow et al., 2007), in contrast to *DUX4*'s importance during early embryogenesis and apparent compatibility with many malignancies. Determining why early embryos and cancer cells can tolerate *DUX4* expression, while muscle cells cannot, may give insight into possible mechanisms for treating FSHD. Another notable difference is the frequent presence of inflammation and lymphocytic infiltration in FSHD muscle (Arahata et al., 1995) versus reduced immune infiltration in DUX4+ cancers. As *DUX4* suppresses MHC class I in both untransformed muscle cells and cancer cells (Figures 5D–5I and S5B–S5D), further work is required to determine why *DUX4* expression results in immune attack in FSHD muscle but immune evasion in cancers.

Our finding of full-length *DUX4* expression and transcriptional activity in diverse solid cancers is mechanistically distinct from

the prior identification of *DUX4* translocations in other cancer types. All DUX4-IGH fusion proteins lack *DUX4*'s C-terminal activation domain and do not activate *DUX4* target gene expression (Lilljebjörn et al., 2016; Liu et al., 2016; Tanaka et al., 2018; Yasuda et al., 2016; Zhang et al., 2016). The CIC-DUX4 fusion protein combines CIC's high mobility group-box DNA-binding domain with the transcriptional activation domain of *DUX4* and so dysregulates CIC target genes but should not activate *DUX4* target gene expression (Specht et al., 2014). While the DUX4-IGH and CIC-DUX4 fusion proteins likely possess oncogenic capacities, neither activates the gene expression program that is characteristic of totipotent embryonic cells expressing full-length *DUX4*.

Since *DUX4* re-expression is common in many cancers, why has it not been previously detected? First, *DUX4* is a multicopy gene that lies within the D4Z4 macrosatellite repeat array in the subtelomeric region of chromosome 4q (Gabriëls et al., 1999; Lee et al., 1995). The repetitive nature of *DUX4*'s genomic locus and its highly variable copy number in the human population (Wijmenga et al., 1993) render it difficult to study, possibly hindering its prior identification as a cancer-specific gene. The continued development of experimental and computational techniques for querying repetitive genomic loci may facilitate the identification of additional genes like *DUX4* that play unexpected roles in cancer. Second, the *DUX4* mRNA is rapidly turned over by nonsense-mediated decay (Feng et al., 2015) and is present at relatively low abundance in its normal developmental context as well as in cancers. Third, because the cleavage-stage embryonic transcriptome that *DUX4* activates was only recently characterized (De Iaco et al., 2017; Hendrickson et al., 2017; Whiddon et al., 2017), it would not have been revealed by GO-like enrichment analyses of cancer-expressed genes. For all of these reasons, quantifying expression of the genes that we identified as robust *DUX4* targets in both embryos and cancers (Table S3) may prove to be an efficient method for identifying *DUX4*-expressing cancers.

Our data implicate *DUX4* in MHC class I-dependent antigen presentation but do not exclude the possibility that *DUX4* regulates tumor-immune interactions via other mechanisms as well. For example, *DUX4* could influence T cell exclusion from the tumor microenvironment. We noted that many DUX4+ cancers exhibited reduced levels of the chemoattractants CXCL9 and CXCL10 (Figure S5G), which promote lymphocyte recruitment to tumors (Homey et al., 2002). We experimentally confirmed that *DUX4* prevented interferon- γ -stimulated increases in CXCL9 and CXCL10 mRNA in myoblasts (Figure S5H), suggesting that *DUX4* may influence chemokine signaling in addition to altering antigen presentation. Further work is required to confirm that *DUX4* influences CXCL9 and CXCL10 levels in cancer cells and identify all of the potentially diverse means by which *DUX4* contributes to immune evasion.

In addition to facilitating immune evasion, *DUX4* might promote tumorigenesis through additional mechanisms that regulate normal early embryonic development. For example, the *DUX4* target *ZSCAN4* is required for telomere maintenance and extension in embryonic stem cells (Zalzman et al., 2010). *ZSCAN4* is activated in most DUX4+ solid cancers, where it may similarly contribute to the replicative potential of these

cancers. Another example is the DUX4 target *CCNA1*, which encodes an A-type cyclin that is essential for male meiosis (Liu et al., 1998) and aberrantly expressed in many myeloid malignancies (Krämer et al., 1998). Ectopic expression of *CCNA1* in the murine hematopoietic lineage caused abnormal myelopoiesis and sporadic progression to acute myeloid leukemia (Liao et al., 2001). These are just two examples illustrating how DUX4 targets' normal roles in the totipotent cleavage-stage embryo and germ cells may contribute to tumorigenesis. While the functional roles of many DUX4 target genes (Table S3) are undefined, we hypothesize that other DUX4 targets may directly contribute to cancer initiation and progression.

As others have long noted, preimplantation embryos bear many qualitative similarities to malignant cells, including de- or re-programming of cell state, infinite replicative potential, and the capacity to effectively invade other tissues (Ben-Porath et al., 2008; Hanahan and Weinberg, 2000; Monk and Holding, 2001; Pierce, 1983). As DUX4 activates the transcriptional program defining the cleavage stage of early embryogenesis, DUX4 targets and downstream factors presumably enable preimplantation embryos to acquire these cancer-like characteristics. DUX4's ability to suppress MHC class I-dependent antigen presentation provides a mechanistic connection between preimplantation development and immune evasion, which is now widely recognized as a hallmark of cancer (Hanahan and Weinberg, 2011). Our discovery that diverse cancers express transcriptionally active DUX4 suggests a model whereby re-expression of an embryonic transcription factor activates an early developmental program characteristic of totipotent cells, resulting in the transformation of somatic cells into malignancies that can evade immune destruction.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- LEAD CONTACT AND MATERIALS AVAILABILITY
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
 - Cell Lines
 - Cell Culture
- METHOD DETAILS
 - Data Sources
 - RNA-seq Library Preparation
 - Genome annotation, RNA-seq and ChIP-seq Read Mapping, and Gene Expression Estimation
 - Cancer-Specific Expression Score
 - DUX4 Polyadenylation Site Usage
 - Somatic Mutation Analysis
 - DUX4 and DUX4C Comparison
 - DUX4 and DUX4-s Isoform Comparison
 - DUXB Differential Gene Expression Analysis
 - DUX4 Differential Gene Expression Analysis
 - Differential Gene Expression and Gene Ontology Analyses
 - Quantification of Immune Cell Infiltration
 - Cloning
 - siRNA Transfection

- MHC Class I Immunoblotting and Induction by Interferon- γ
- Real-Time qPCR
- Flow Cytometry
- Antibodies
- Primers
- siRNAs
- Survival analyses
- QUANTIFICATION AND STATISTICAL ANALYSIS
 - Data Analysis and Visualization
- DATA AND CODE AVAILABILITY
 - Experimental Data and Plasmids
 - Accession Codes

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.devcel.2019.06.011>.

ACKNOWLEDGMENTS

We thank Heidi Dvinge for TCGA transcriptome analyses, Sean Bennett and S. Jessica Kumar for technical assistance, and Sujatha Jagannathan and Shirleen Soh for manuscript feedback. This research was supported in part by NIH/NINDS P01 NS069539 (R.K.B., S.J.T., and N.A.S.), NIH/NIAMS R01 AR045203 (S.J.T., S.C.S., and A.E.C.), Friends of FSH Research (A.E.C. and S.J.T.), and the Chris Carrino Foundation for FSHD (S.J.T. and A.E.C.). R.K.B. is a Scholar of The Leukemia & Lymphoma Society (1344–18). G.-L.C. is a Mahan Fellow. The results shown here are in part based upon data generated by the TCGA Research Network: <https://cancergenome.nih.gov/>. The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS.

AUTHOR CONTRIBUTIONS

G.-L.C. performed computational analyses. A.E.C., E.D.N., N.A.S., and S.C.S. performed experiments. G.-L.C., A.E.C., S.J.T., and R.K.B. wrote the paper.

DECLARATION OF INTERESTS

G.-L.C., A.E.C., S.J.T., and R.K.B. are inventors on a provisional patent application submitted by Fred Hutchinson Cancer Research Center that covers DUX4 expression in cancers and response to immunotherapy.

Received: August 9, 2018

Revised: April 22, 2019

Accepted: June 14, 2019

Published: July 18, 2019

REFERENCES

- Adzhubei, I.A., Schmidt, S., Peshkin, L., Ramensky, V.E., Gerasimova, A., Bork, P., Kondrashov, A.S., and Sunyaev, S.R. (2010). A method and server for predicting damaging missense mutations. *Nat. Methods* 7, 248–249.
- Arahata, K., Ishihara, T., Fukunaga, H., Orimo, S., Lee, J.H., Goto, K., and Nonaka, I. (1995). Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses. *Muscle Nerve Suppl.* 18, S56–S66.
- Ben-Porath, I., Thomson, M.W., Carey, V.J., Ge, R., Bell, G.W., Regev, A., and Weinberg, R.A. (2008). An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. *Nat. Genet.* 40, 499–507.
- Bray, N.L., Pimentel, H., Melsted, P., and Pachter, L. (2016). Near-optimal probabilistic RNA-seq quantification. *Nat. Biotechnol.* 34, 525–527.
- Caballero, O.L., and Chen, Y.T. (2009). Cancer/testis (CT) antigens: potential targets for immunotherapy. *Cancer Sci.* 100, 2014–2021.

- Campbell, A.E., Shadle, S.C., Jagannathan, S., Lim, J.W., Resnick, R., Tawil, R., van der Maarel, S.M., and Tapscott, S.J. (2018). NuRD and CAF-1-mediated silencing of the D4Z4 array is modulated by DUX4-induced MBD3L proteins. *ELife* 7, e31023.
- Chang, T.C., Yang, Y., Yasue, H., Bharti, A.K., Retzel, E.F., and Liu, W.S. (2011). The expansion of the PRAME gene family in Eutheria. *PLoS One* 6, e16867.
- Choi, S.H., Gearhart, M.D., Cui, Z., Bosnakovski, D., Kim, M., Schennum, N., and Kyba, M. (2016). DUX4 recruits p300/CBP through its C-terminus and induces global H3K27 acetylation changes. *Nucleic Acids Res.* 44, 5161–5173.
- Cibulskis, K., Lawrence, M.S., Carter, S.L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E.S., and Getz, G. (2013). Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. *Nat. Biotechnol.* 31, 213–219.
- Colaprico, A., Silva, T.C., Olsen, C., Garofano, L., Cava, C., Garolini, D., Sabedot, T.S., Malta, T.M., Pagnotta, S.M., Castiglioni, I., et al. (2016). TCGAAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. *Nucleic Acids Res.* 44, e71.
- Das, S., and Chadwick, B.P. (2016). Influence of repressive histone and DNA methylation upon D4Z4 transcription in non-myogenic cells. *PLoS One* 11, e0160022.
- Daxinger, L., Harten, S.K., Oey, H., Epp, T., Isbel, L., Huang, E., Whitelaw, N., Apedaille, A., Sorolla, A., Yong, J., et al. (2013). An ENU mutagenesis screen identifies novel and known genes involved in epigenetic processes in the mouse. *Genome Biol.* 14, R96.
- De Iaco, A., Coudray, A., Duc, J., and Trono, D. (2019). DPPA2 and DPPA4 are necessary to establish a 2C-like state in mouse embryonic stem cells. *EMBO Rep.* 20, e47382.
- De Iaco, A., Planet, E., Coluccio, A., Verp, S., Duc, J., and Trono, D. (2017). DUX-family transcription factors regulate zygotic genome activation in placental mammals. *Nat. Genet.* 49, 941–945.
- Dvinge, H., Ries, R.E., Ilagan, J.O., Stirewalt, D.L., Meshinchi, S., and Bradley, R.K. (2014). Sample processing obscures cancer-specific alterations in leukemic transcriptomes. *Proc. Natl. Acad. Sci. USA* 111, 16802–16807.
- Eckersley-Maslin, M., Alda-Catalinas, C., Blotenburg, M., Kreibich, E., Krueger, C., and Reik, W. (2019). Dppa2 and Dppa4 directly regulate the Dux-driven zygotic transcriptional program. *Genes Dev.* 33, 194–208.
- Eidahl, J.O., Giesige, C.R., Domire, J.S., Wallace, L.M., Fowler, A.M., Guckes, S.M., Garwick-Coppens, S.E., Labhart, P., and Harper, S.Q. (2016). Mouse Dux is myotoxic and shares partial functional homology with its human paralog DUX4. *Hum. Mol. Genet.* 25, 4577–4589.
- Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur. J. Cancer* 45, 228–247.
- Feng, Q., Snider, L., Jagannathan, S., Tawil, R., van der Maarel, S.M., Tapscott, S.J., and Bradley, R.K. (2015). A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy. *ELife* 4.
- Flicek, P., Ahmed, I., Amode, M.R., Barrell, D., Beal, K., Brent, S., Carvalho-Silva, D., Clapham, P., Coates, G., Fairley, S., et al. (2013). Ensembl 2013. *Nucleic Acids Res.* 41, D48–D55.
- Friedman, R.L., Manly, S.P., McMahon, M., Kerr, I.M., and Stark, G.R. (1984). Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. *Cell* 38, 745–755.
- Gabriëls, J., Beckers, M.C., Ding, H., De Vriese, A., Plaisance, S., van der Maarel, S.M., Padberg, G.W., Frants, R.R., Hewitt, J.E., Collen, D., et al. (1999). Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. *Gene* 236, 25–32.
- Gao, J., Shi, L.Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S.E., et al. (2016). Loss of IFN- γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. *Cell* 167, 397–404.e9.
- Geng, L.N., Tyler, A.E., and Tapscott, S.J. (2011). Immunodetection of human double homeobox 4. *Hybridoma (Larchmt)* 30, 125–130.
- Geng, L.N., Yao, Z., Snider, L., Fong, A.P., Cech, J.N., Young, J.M., van der Maarel, S.M., Ruzzo, W.L., Gentleman, R.C., Tawil, R., et al. (2012). DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. *Dev. Cell* 22, 38–51.
- Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. *Cell* 100, 57–70.
- Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. *Cell* 144, 646–674.
- Hayashi, H., Arai, T., Togashi, Y., Kato, H., Fujita, Y., De Velasco, M.A., Kimura, H., Matsumoto, K., Tanaka, K., Okamoto, I., et al. (2015). The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer. *Oncogene* 34, 199–208.
- Haynes, P., Bomsztyk, K., and Miller, D.G. (2018). Sporadic DUX4 expression in FSHD myocytes is associated with incomplete repression by the PRC2 complex and gain of H3K9 acetylation on the contracted D4Z4 allele. *Epigenet. Chromatin* 11, 47.
- Hendrickson, P.G., Dorais, J.A., Grow, E.J., Whiddon, J.L., Lim, J.-W., Wike, C.L., Weaver, B.D., Pflueger, C., Emery, B.R., Wilcox, A.L., et al. (2017). Conserved roles of mouse DUX and human DUX4 in activating cleavage-stage genes and MERV1/HERV1 retrotransposons. *Nat. Genet.* 49, 925–934.
- Homey, B., Müller, A., and Zlotnik, A. (2002). Chemokines: agents for the immunotherapy of cancer? *Nat. Rev. Immunol.* 2, 175–184.
- Huber, W., Carey, V.J., Gentleman, R., Anders, S., Carlson, M., Carvalho, B.S., Bravo, H.C., Davis, S., Gatto, L., Girke, T., et al. (2015). Orchestrating high-throughput genomic analysis with Bioconductor. *Nat. Methods* 12, 115–121.
- Hugo, W., Zaretsky, J.M., Sun, L., Song, C., Moreno, B.H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016). Genomic and Transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. *Cell* 165, 35–44.
- Huichalaf, C., Micheloni, S., Ferri, G., Caccia, R., and Gabellini, D. (2014). DNA methylation analysis of the macrosatellite repeat associated with FSHD muscular dystrophy at single nucleotide level. *PLoS One* 9, e115278.
- Ikeda, H., Lethé, B., Lehmann, F., van Baren, N., Baurain, J.F., de Smet, C., Chambost, H., Vitale, M., Moretta, A., Boon, T., et al. (1997). Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. *Immunity* 6, 199–208.
- Jagannathan, S., Shadle, S.C., Resnick, R., Snider, L., Tawil, R.N., van der Maarel, S.M., Bradley, R.K., and Tapscott, S.J. (2016). Model systems of DUX4 expression recapitulate the transcriptional profile of FSHD cells. *Hum. Mol. Genet.*
- Katz, Y., Wang, E.T., Airolidi, E.M., and Burge, C.B. (2010). Analysis and design of RNA sequencing experiments for identifying isoform regulation. *Nat. Methods* 7, 1009–1015.
- Kawamura-Saito, M., Yamazaki, Y., Kaneko, K., Kawaguchi, N., Kanda, H., Mukai, H., Gotoh, T., Motoi, T., Fukayama, M., Aburatani, H., et al. (2006). Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation. *Hum. Mol. Genet.* 15, 2125–2137.
- Kayisli, U.A., Selam, B., Guzeloglu-Kayisli, O., Demir, R., and Arici, A. (2003). Human chorionic gonadotropin contributes to maternal immunotolerance and endometrial apoptosis by regulating Fas-Fas ligand system. *J. Immunol.* 171, 2305–2313.
- Kim, M.S., Pinto, S.M., Getnet, D., Nirujogi, R.S., Manda, S.S., Chaerkady, R., Madugundu, A.K., Kelkar, D.S., Isserlin, R., Jain, S., et al. (2014). A draft map of the human proteome. *Nature* 509, 575–581.
- Kosti, I., Jain, N., Aran, D., Butte, A.J., and Sirota, M. (2016). Cross-tissue analysis of gene and protein expression in normal and cancer tissues. *Sci. Rep.* 6, 24799.
- Kowaljow, V., Marcowycz, A., Ansseau, E., Conde, C.B., Sauvage, S., Mattéotti, C., Arias, C., Corona, E.D., Nuñez, N.G., Leo, O., et al. (2007). The

- DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein. *Neuromuscul. Disord.* **17**, 611–623.
- Krämer, A., Hochhaus, A., Saussele, S., Reichert, A., Willer, A., and Hehlmann, R. (1998). Cyclin A1 is predominantly expressed in hematological malignancies with myeloid differentiation. *Leukemia* **12**, 893–898.
- Kruse, V., Hamann, C., Monecke, S., Cyganek, L., Elsner, L., Hübscher, D., Walter, L., Streckfuss-Bömeke, K., Guan, K., and Dressel, R. (2015). Human induced pluripotent stem cells are targets for allogeneic and autologous natural killer (NK) cells and killing is partly mediated by the activating NK receptor DNAM-1. *PLoS One* **10**, e0125544.
- Langmead, B., Trapnell, C., Pop, M., and Salzberg, S.L. (2009). Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol.* **10**, R25.
- Lee, J.H., Goto, K., Matsuda, C., and Arahata, K. (1995). Characterization of a tandemly repeated 3.3-kbKpnI unit in the facioscapulohumeral muscular dystrophy (FSHD) gene region on chromosome 4q35. *Muscle Nerve* **18**, S6–S13.
- Lemmers, R.J.L.F., Tawil, R., Petek, L.M., Balog, J., Block, G.J., Santen, G.W.E., Amell, A.M., van der Vliet, P.J., Almomani, R., Straasheijm, K.R., et al. (2012). Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. *Nat. Genet.* **44**, 1370–1374.
- Lemmers, R.J.L.F., van der Vliet, P.J., Klooster, R., Sacconi, S., Camaño, P., Dauwerse, J.G., Snider, L., Straasheijm, K.R., Jan van Ommen, G.J., Padberg, G.W., et al. (2010). A unifying genetic model for facioscapulohumeral muscular dystrophy. *Science* **329**, 1650–1653.
- Lemmers, R.J.L.F., Wohlgemuth, M., van der Gaag, K.J., van der Vliet, P.J., van Teijlingen, C.M.M., de Knijff, P., Padberg, G.W., Frants, R.R., and van der Maarel, S.M. (2007). Specific sequence variations within the 4q35 region are associated with facioscapulohumeral muscular dystrophy. *Am. J. Hum. Genet.* **81**, 884–894.
- Li, B., and Dewey, C.N. (2011). RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC Bioinformatics* **12**, 323.
- Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., and Durbin, R.; 1000 Genome Project Data Processing Subgroup (2009). The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078–2079.
- Li, T., Fan, J., Wang, B., Traugh, N., Chen, Q., Liu, J.S., Li, B., and Liu, X.S. (2017). TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. *Cancer Res.* **77**, e108–e110.
- Liao, C., Wang, X.Y., Wei, H.Q., Li, S.Q., Merghoub, T., Pandolfi, P.P., and Wolgemuth, D.J. (2001). Altered myelopoiesis and the development of acute myeloid leukemia in transgenic mice overexpressing cyclin A1. *Proc. Natl. Acad. Sci. USA* **98**, 6853–6858.
- Lilljebjörn, H., Henningsson, R., Hyrenius-Wittsten, A., Olsson, L., Orsmark-Pietras, C., von Palffy, S., Askmyr, M., Rissler, M., Schrappe, M., Cario, G., et al. (2016). Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. *Nat. Commun.* **7**, 11790.
- Liu, D., Matzuk, M.M., Sung, W.K., Guo, Q., Wang, P., and Wolgemuth, D.J. (1998). Cyclin A1 is required for meiosis in the male mouse. *Nat. Genet.* **20**, 377–380.
- Liu, Y.-F., Wang, B.-Y., Zhang, W.-N., Huang, J.-Y., Li, B.-S., Zhang, M., Jiang, L., Li, J.-F., Wang, M.-J., Dai, Y.-J., et al. (2016). Genomic profiling of adult and pediatric B-cell acute lymphoblastic leukemia. *EBioMedicine* **8**, 173–183.
- Livak, K.J., and Schmittgen, T.D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2⁻(Delta Delta C(T)) Method. *Methods* **25**, 402–408.
- Manguso, R.T., Pope, H.W., Zimmer, M.D., Brown, F.D., Yates, K.B., Miller, B.C., Collins, N.B., Bi, K., LaFleur, M.W., Juneja, V.R., et al. (2017). In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. *Nature* **547**, 413–418.
- Meissner, T.B., Li, A., Biswas, A., Lee, K.H., Liu, Y.J., Bayir, E., Iliopoulos, D., van den Elsen, P.J., and Kobayashi, K.S. (2010). NLR family member NLRC5 is a transcriptional regulator of MHC class I genes. *Proc. Natl. Acad. Sci. USA* **107**, 13794–13799.
- Meyer, L.R., Zweig, A.S., Hinrichs, A.S., Karolchik, D., Kuhn, R.M., Wong, M., Sloan, C.A., Rosenbloom, K.R., Roe, G., Rhead, B., et al. (2013). The UCSC Genome Browser database: extensions and updates 2013. *Nucleic Acids Res.* **41**, D64–D69.
- Monk, M., and Holding, C. (2001). Human embryonic genes re-expressed in cancer cells. *Oncogene* **20**, 8085–8091.
- Newman, A.M., Liu, C.L., Green, M.R., Gentles, A.J., Feng, W., Xu, Y., Hoang, C.D., Diehn, M., and Alizadeh, A.A. (2015). Robust enumeration of cell subsets from tissue expression profiles. *Nat. Methods* **12**, 453–457.
- Ottaviani, A., Rival-Gervier, S., Boussouar, A., Foerster, A.M., Rondier, D., Sacconi, S., Desnuelle, C., Gilson, E., and Magdinier, F. (2009). The D4Z4 macrosatellite repeat acts as a CTCF and A-type lamins-dependent insulator in facio-scapulo-humeral dystrophy. *PLoS Genet.* **5**, e1000394.
- Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R.E., Luoma, A.M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018). A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. *Science* **359**, 770–775.
- Patel, S.J., Sanjana, N.E., Kishton, R.J., Eidizadeh, A., Vodnala, S.K., Cam, M., Gartner, J.J., Jia, L., Steinberg, S.M., Yamamoto, T.N., et al. (2017). Identification of essential genes for cancer immunotherapy. *Nature* **548**, 537–542.
- Pierce, G.B. (1983). The cancer cell and its control by the embryo. *Am. J. Pathol. Rous-Whipple Award lecture* **113**, 117–124.
- Pollack, S.M., Li, Y., Blaisdell, M.J., Farrar, E.A., Chou, J., Hoch, B.L., Loggers, E.T., Rodler, E., Eary, J.F., Conrad, E.U., et al. (2012). NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycytidine. *PLoS One* **7**, e32165.
- Preussner, J., Zhong, J., Sreenivasan, K., Günther, S., Engleitner, T., Künne, C., Glatzel, M., Rad, R., Looso, M., Braun, T., et al. (2018). Oncogenic amplification of zygotic dux factors in regenerating p53-deficient muscle stem cells defines a molecular cancer subtype. *Cell Stem Cell* **23**, 794–805.e4.
- Revenkova, E., Eijpe, M., Heyting, C., Gross, B., and Jessberger, R. (2001). Novel meiosis-specific isoform of mammalian SMC1. *Mol. Cell. Biol.* **21**, 6984–6998.
- Ribas, A., and Wolchok, J.D. (2018). Cancer immunotherapy using checkpoint blockade. *Science* **359**, 1350–1355.
- Rickard, A.M., Petek, L.M., and Miller, D.G. (2015). Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways. *Hum. Mol. Genet.*
- Robinson, M.D., and Oshlack, A. (2010). A scaling normalization method for differential expression analysis of RNA-seq data. *Genome Biol.* **11**, R25.
- Rodig, S.J., Gusenleitner, D., Jackson, D.G., Gjini, E., Giobbie-Hurder, A., Jin, C., Chang, H., Lovitch, S.B., Horak, C., Weber, J.S., et al. (2018). MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. *Sci. Transl. Med.* **10**, eaar3342.
- Rooney, M.S., Shukla, S.A., Wu, C.J., Getz, G., and Hacohen, N. (2015). Molecular and genetic properties of tumors associated with local immune cytolytic activity. *Cell* **160**, 48–61.
- Sade-Feldman, M., Jiao, Y.J., Chen, J.H., Rooney, M.S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S.L., Hammond, M.R., Vitzthum, H., Blackmon, S.M., et al. (2017). Resistance to checkpoint blockade therapy through inactivation of antigen presentation. *Nat. Commun.* **8**, 1136.
- Sakaguchi, S., Yamaguchi, T., Nomura, T., and Ono, M. (2008). Regulatory T cells and immune tolerance. *Cell* **133**, 775–787.
- Schroder, K., Hertzog, P.J., Ravasi, T., and Hume, D.A. (2004). Interferon-gamma: an overview of signals, mechanisms and functions. *J. Leukoc. Biol.* **75**, 163–189.
- Shadle, S.C., Zhong, J.W., Campbell, A.E., Conerly, M.L., Jagannathan, S., Wong, C.-J., Morello, T.D., van der Maarel, S.M., and Tapscott, S.J. (2017). DUX4-induced dsRNA and MYC mRNA stabilization activate apoptotic pathways in human cell models of facioscapulohumeral dystrophy. *PLoS Genet.* **13**, e1006658.

- Sharma, P., Hu-Lieskovan, S., Wargo, J.A., and Ribas, A. (2017). Primary, adaptive, and acquired resistance to cancer immunotherapy. *Cell* 168, 707–723.
- Sheng, W., LaFleur, M.W., Nguyen, T.H., Chen, S., Chakravarthy, A., Conway, J.R., Li, Y., Chen, H., Yang, H., Hsu, P.-H., et al. (2018). LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade. *Cell* 174, 549–563.e19.
- Shukla, S.A., Rooney, M.S., Rajasagi, M., Tiao, G., Dixon, P.M., Lawrence, M.S., Stevens, J., Lane, W.J., Dellagatta, J.L., Steelman, S., et al. (2015). Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. *Nat. Biotechnol.* 33, 1152–1158.
- Smith, H.A., and McNeel, D.G. (2010). The SSX family of cancer-testis antigens as target proteins for tumor therapy. *Clin. Dev. Immunol.* 2010, 150591.
- Snider, L., Geng, L.N., Lemmers, R.J.L.F., Kyba, M., Ware, C.B., Nelson, A.M., Tawil, R., Filippova, G.N., van der Maarel, S.M., Tapscott, S.J., et al. (2010). Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. *PLoS Genet.* 6, e1001181.
- Specht, K., Sung, Y.-S., Zhang, L., Richter, G.H.S., Fletcher, C.D., and Antonescu, C.R. (2014). Distinct transcriptional signature and immunoprofile of CIC-DUX4 fusion-positive round cell tumors compared to EWSR1-rearranged Ewing sarcomas: further evidence toward distinct pathologic entities. *Genes Chromosomes Cancer* 53, 622–633.
- Spranger, S., Bao, R., and Gajewski, T.F. (2015). Melanoma-intrinsic β -catenin signalling prevents anti-tumour immunity. *Nature* 523, 231–235.
- Stadler, G., Chen, J.C., Wagner, K., Robin, J.D., Shay, J.W., Emerson, C.P., Jr., and Wright, W.E. (2011). Establishment of clonal myogenic cell lines from severely affected dystrophic muscles - CDK4 maintains the myogenic population. *Skelet. Muscle* 1, 12.
- Stenman, U.-H., Alfthan, H., and Hotakainen, K. (2004). Human chorionic gonadotropin in cancer. *Clin. Biochem.* 37, 549–561.
- Tanaka, Y., Kawazu, M., Yasuda, T., Tamura, M., Hayakawa, F., Kojima, S., Ueno, T., Kiyoi, H., Naoe, T., and Mano, H. (2018). Transcriptional activities of DUX4 fusions in B-cell acute lymphoblastic leukemia. *Haematologica* 103, e522–e526.
- Therneau, T.M., and Grambsch, P.M. (2000). Modeling survival data: extending the cox model (Springer).
- Thorsen, V., Gibbs, D.L., Brown, S.D., Wolf, D., Bortone, D.S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G.F., Plaisier, C.L., Eddy, J.A., et al. (2018). The immune landscape of cancer. *Immunity* 48, 812–830.e14.
- Thorvaldsdottir, H., Robinson, J.T., and Mesirov, J.P. (2013). Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. *Brief. Bioinform.* 14, 178–192.
- Topalian, S.L., Drake, C.G., and Pardoll, D.M. (2015). Immune checkpoint blockade: a common denominator approach to cancer therapy. *Cancer Cell* 27, 450–461.
- Townsend, A., Ohlén, C., Bastin, J., Ljunggren, H.G., Foster, L., and Kärre, K. (1989). Association of class I major histocompatibility heavy and light chains induced by viral peptides. *Nature* 340, 443–448.
- Trapnell, C., Pachter, L., and Salzberg, S.L. (2009). TopHat: discovering splice junctions with RNA-Seq. *Bioinformatics* 25, 1105–1111.
- Van Allen, E.M., Miao, D., Schilling, B., Shukla, S.A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M.H.G., Goldinger, S.M., et al. (2015). Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. *Science* 350, 207–211.
- Wagenmakers, E.-J., Lodewyckx, T., Kuriyal, H., and Grasman, R. (2010). Bayesian hypothesis testing for psychologists: a tutorial on the Savage-Dickey method. *Cogn. Psychol.* 60, 158–189.
- Wang, X., Spandidos, A., Wang, H., and Seed, B. (2012). PrimerBank: a PCR primer database for quantitative gene expression analysis, 2012 update. *Nucleic Acids Res.* 40, D1144–D1149.
- Whiddon, J.L., Langford, A.T., Wong, C.-J., Zhong, J.W., and Tapscott, S.J. (2017). Conservation and innovation in the DUX4-family gene network. *Nat. Genet.*
- Wickham, H. (2016). ggplot2: Elegant Graphics for Data Analysis (New York, NY: Springer-Verlag).
- Wickham H, François R, Henry L and Müller K (2018). dplyr: A Grammar of Data Manipulation. <https://CRAN.R-project.org/package=dplyr>.
- Wijmenga, C., Frants, R.R., Hewitt, J.E., van Deutekom, J.C.T., van Geel, M., Wright, T.J., Padberg, G.W., Hofker, M.H., and van Ommen, G.B. (1993). Molecular genetics of facioscapulohumeral muscular dystrophy. *Neuromuscul. Disord.* 3, 487–491.
- Wolchok, J.D., Hoos, A., O'Day, S., Weber, J.S., Hamid, O., Lebbe, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009). Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. *Clin. Cancer Res.* 15, 7412–7420.
- Yasuda, T., Tsuzuki, S., Kawazu, M., Hayakawa, F., Kojima, S., Ueno, T., Imoto, N., Kohsaka, S., Kunita, A., Doi, K., et al. (2016). Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. *Nat. Genet.* 48, 569–574.
- Young, J.M., Whiddon, J.L., Yao, Z., Kasinathan, B., Snider, L., Geng, L.N., Balog, J., Tawil, R., van der Maarel, S.M., and Tapscott, S.J. (2013). DUX4 binding to retroelements creates promoters that are active in FSHD muscle and testis. *PLoS Genet.* 9, e1003947.
- Young, M.D., Wakefield, M.J., Smyth, G.K., and Oshlack, A. (2010). Gene ontology analysis for RNA-seq: accounting for selection bias. *Genome Biol.* 11, R14.
- Zalzman, M., Falco, G., Sharova, L.V., Nishiyama, A., Thomas, M., Lee, S.-L., Stagg, C.A., Hoang, H.G., Yang, H.-T., Indig, F.E., et al. (2010). Zscan4 regulates telomere elongation and genomic stability in ES cells. *Nature* 464, 858–863.
- Zaretsky, J.M., Garcia-Diaz, A., Shin, D.S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D.Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016). Mutations associated with acquired resistance to PD-1 blockade in melanoma. *N. Engl. J. Med.* 375, 819–829.
- Zeisel, A., Yizhaky, A., Bossel Ben-Moshe, N., and Domany, E. (2013). An accessible database for mouse and human whole transcriptome qPCR primers. *Bioinformatics* 29, 1355–1356.
- Zeng, W., de Greef, J.C., Chen, Y.-Y., Chien, R., Kong, X., Gregson, H.C., Winokur, S.T., Pyle, A., Robertson, K.D., Schmiesing, J.A., et al. (2009). Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD). *PLoS Genet.* 5, e1000559.
- Zhang, J., McCastlain, K., Yoshihara, H., Xu, B., Chang, Y., Churchman, M.L., Wu, G., Li, Y., Wei, L., Iacobucci, I., et al. (2016). Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. *Nat. Genet.* 48, 1481–1489.
- Zhang, X., Ding, L., and Sandford, A.J. (2005). Selection of reference genes for gene expression studies in human neutrophils by real-time PCR. *BMC Mol. Biol.* 6, 4.
- Zhang, Y., Liu, T., Meyer, C.A., Eickhout, J., Johnson, D.S., Bernstein, B.E., Nussbaum, C., Myers, R.M., Brown, M., Li, W., et al. (2008). Model-based analysis of ChIP-Seq (MACS). *Genome Biol.* 9, R137.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
GAPDH (6C5)	GeneTex	GTX28245; RRID: AB_370675
MHC class I (F-3)	Santa Cruz Biotechnology	sc-55582; RRID: AB_831547
FITC anti-human HLA-A,B,C (W6/32)	BioLegend	311404; RRID: AB_314873
ZSCAN4	Invitrogen	PA5-32106; RRID: AB_2549579
DUX4 (14-3)	Geng et al., 2011	N/A
Peroxidase AffiniPure Goat Anti-Mouse IgG (H+L)	Jackson ImmunoResearch	115-035-146; RRID: AB_2307392
Peroxidase AffiniPure Goat Anti-Rabbit (H+L)	Jackson ImmunoResearch	111-035-144; RRID: AB_2307391
Chemicals, Peptides, and Recombinant Proteins		
Insulin	Sigma-Aldrich	I1882
Recombinant human basic fibroblast growth factor	Promega	G5071
Dexamethasone	Sigma-Aldrich	D4902
Puromycin dihydrochloride	Sigma-Aldrich	P8833
Doxycycline hyclate	Sigma-Aldrich	D9891
Recombinant human IFN-gamma	R&D Systems	285IF100
Polybrene	Sigma-Aldrich	107689
Penicillin/streptomycin	Gibco/Thermo Fisher	15140122
Sodium Pyruvate	Gibco/Thermo Fisher	11360070
DNase I	Gibco/Thermo Fisher	18068015
MEM Non-Essential Amino Acids Solution	Gibco/Thermo Fisher	11140050
Critical Commercial Assays		
Lipofectamine RNAiMAX	Life Technologies	13778150
SuperScriptIII First-Strand System	Life Technologies	18080051
iTaq SYBR Green Supermix	Bio-Rad	1725124
TruSeq RNA Library Preparation Kit	Illumina	RS-122-2001
NucleoSpin RNA kit	Machery-Nagel	740955
Key Instruments		
QuantStudio 7 Flex	Applied Biosystems	N/A
4200 TapeStation System	Agilent Technologies	N/A
Trinean DropSense 96 UV-Vis spectrophotometer	Caliper Life Sciences	N/A
Qubit 2.0 Fluorometer	Life Technologies	N/A
HiSeq 2500	Illumina	N/A
LSRFortessa X-50	BD Biosciences	N/A
Source Data		
The Cancer Genome Atlas RNA-seq data	CGHub	RRID: SCR_002657
RNA-seq data for Eidahl et al., 2016 ; Hendrickson et al., 2017 ; Hugo et al., 2016	NCBI Gene Expression Omnibus	GSE85632, GSE85935, GSE78220; RRID: SCR_005012
RNA-seq data for Rickard et al., 2015	NCBI Sequence Read Archive	SRP058319; RRID: SCR_004891
RNA-seq data for Van Allen et al., 2015	dbGaP	phs000452.v2.p1; RRID: SCR_002709
RNA-seq data for Yasuda et al., 2016	Japanese Genotype-Phenotype Archive	JGAS00000000047; RRID: SCR_003118
RNA-seq data for Lilljebjörn et al., 2016	European Genome-phenome Archive	EGAD00001002112; RRID: SCR_004944

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
GTEX Sample Annotations and Gene Expression	GTEX portal	www.gtexportal.org ; RRID: SCR_013042
ChIP-seq data for Geng et al., 2012	NCBI Gene Expression Omnibus	GSE33838; RRID: SCR_005012
Deposited Data		
RNA-seq data for this study	NCBI Gene Expression Omnibus	GSE128917; RRID: SCR_005012
Experimental Models: Cell Lines		
MB135 cells (female)	Snider et al., 2010	N/A
MB2401 cells (male)	Campbell et al., 2018	N/A
MB073 cells (male)	Campbell et al., 2018	N/A
A204 cells (female)	ATCC	HTB-82; RRID: CVCL_1058
HeLa cells (female)	ATCC	CCL-2; RRID: CVCL_0030
MCF-7 cells (female)	ATCC	HTB-22; RRID: CVCL_0031
Mel375 cells (female) and Mel526 cells (unknown)	Dr. Seth Pollack (Pollack et al., 2012)	N/A
SuSa cells (male)	DSMZ	ACC 747; RRID: CVCL_L280
MB135iDUX4 cells (female)	Jagannathan et al., 2016	N/A
MB135iDUXB cells (female)	This study	N/A
A204iDUX4 cells (female)	This study	N/A
HeLaiDUX4 cells (female)	This study	N/A
MCF-7iDUX4 cells (female)	This study	N/A
Mel375iDUX4 cells (female)	This study	N/A
Mel526iDUX4 cells (unknown)	This study	N/A
SuSaiDUX4 cells (male)	This study	N/A
Oligonucleotides		
Primers for qPCR and cloning See STAR Methods for sequences	This study	N/A
FlexiTube GeneSolution siRNAs targeting PRPF8 See STAR Methods for sequences	Qiagen	GS10594
Non-targeting Negative Control siRNA See STAR Methods for sequence	Qiagen	1022076
Recombinant DNA		
pCW57.1	Addgene	41397; RRID: Addgene_41397
pCW57.1-DUX4-CA	Addgene	99281; RRID: Addgene_99281
pCW57.1-DUXB-CA	This study, available on Addgene	125027; RRID: Addgene_125027
Software and Algorithms		
Bowtie v1.0.0	Langmead et al, 2009	github.com/BenLangmead/bowtie/ ; RRID: SCR_005476
RSEM v.1.2.4	Li and Dewey, 2011	deweylab.github.io/RSEM/ ; RRID: SCR_013027
TopHat v2.0.8b	Trapnell et al, 2009	ccb.jhu.edu/software/tophat/index.shtml ; RRID: SCR_013035
MISO v2.0	Katz et al., 2010	genes.mit.edu/burgelab/miso/ ; RRID: SCR_003124
Samtools v1.3.1	Li et al., 2009	www.htslib.org ; RRID: SCR_002105
Kallisto v0.43.0	Bray et al., 2016	pachterlab.github.io/kallisto/ ; RRID: SCR_016582
MACS v2.1.1.20160309	Zhang et al., 2008	github.com/taoliu/MACS/ ; RRID: SCR_013291
IGV v2.3.90	Thorvaldsdottir et al., 2013	software.broadinstitute.org/software/igv/ ; RRID: SCR_011793
Bioconductor	Huber et al., 2015	www.bioconductor.org ; RRID: SCR_006442

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
GOseq	Young et al., 2010	bioconductor.org/packages/release/bioc/html/goseq.html ; RRID: SCR_017052
dplyr	Wickham et al., 2018	CRAN: dplyr; RRID: SCR016708
ggplot2	Wickham, 2016	CRAN: ggplot2; RRID: SCR_014601
GraphPad Prism v7.0	N/A	www.graphpad.com ; RRID: SCR_002798
FlowJo v10.5.3	N/A	www.flowjo.com/solutions/flowjo ; RRID: SCR_008520
BD FACSDiva	N/A	www.bdbiosciences.com/instruments/software/facsddiva/index.jsp ; RRID: SCR_001456

LEAD CONTACT AND MATERIALS AVAILABILITY

Further information and requests for reagents and resources may be directed to and will be fulfilled by the Lead Contact, Dr. Robert K. Bradley, at Fred Hutchinson Cancer Research Center (rbradley@fredhutch.org).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Cell Lines

A204 cells were purchased from ATCC (Cat# HTB-82) and have been cultured in the Tapscott laboratory since 2012. HeLa cells were purchased from ATCC (Cat# CCL-2) and have been cultured long-term in the Tapscott laboratory. All myoblast lines were obtained as de-identified primary cells from the Fields Center for FSHD and Neuromuscular Research at the University of Rochester Medical Center (<https://www.urmc.rochester.edu/neurology/fields-center.aspx>) and immortalized by retroviral transduction of CDK4 and hTERT (Stadler et al., 2011) in the Tapscott laboratory. MB135iDUX4 cells have also been described previously (Jagannathan et al., 2016). MCF-7 cells were purchased from ATCC (Cat# HTB-22) and have been cultured in the Tapscott laboratory since 2017. Mel375 and Mel526 cells were generously provided by Dr. Seth Pollack (Pollack et al., 2012). SuSa cells were purchased from DSMZ (Cat# ACC 747) and have been cultured in the Tapscott laboratory since 2014.

Cell Culture

A204 and A204iDUX4 cells were maintained in RPMI 1640 Medium (Gibco) supplemented with 10% HyClone Fetal Bovine Serum (GE Healthcare Life Sciences), 100 U/100 μ g penicillin/streptomycin (Gibco), and, for A204iDUX4, 1.5 μ g/ml puromycin (Sigma-Aldrich). HeLa and HeLaiDUX4 cells were maintained in Dulbecco's Modified Eagle Medium (Gibco) supplemented with 10% HyClone Fetal Bovine Serum, 100 U/100 μ g penicillin/streptomycin, and, for HeLaiDUX4, 1.5 μ g/ml puromycin. MB2401, MB073, MB135, MB135iDUX4, and MB135iDUXB myoblasts were maintained in Ham's F-10 Nutrient Mix (Gibco) supplemented with 20% HyClone Fetal Bovine Serum, 100 U/100 μ g penicillin/streptomycin (Gibco), 10 ng/ml recombinant human basic fibroblast growth factor (Promega Corporation), 1 μ M dexamethasone (Sigma-Aldrich), and, for MB135iDUX4 and MB135iDUXB, 3 μ g/ml or 2 μ g/ml puromycin (Sigma-Aldrich), respectively. MCF-7 and MCF-7iDUX4 cells were maintained in Eagle's Minimal Essential Medium (Quality Biological) supplemented with 10% HyClone Fetal Bovine Serum, 100 U/100 μ g penicillin/streptomycin, 10 μ g/ml insulin (Sigma-Aldrich), and, for MCF7iDUX4, 1.5 μ g/ml puromycin. Mel375, Mel375iDUX4, Mel526, and Mel526iDUX4 cells were maintained in RPMI 1640 Medium containing HEPES (Gibco) supplemented with 10% HyClone Fetal Bovine Serum, 100 U/100 μ g penicillin/streptomycin, 2 mM L-Glutamine (Gibco), 1% MEM Non-Essential Amino Acids Solution (Gibco), 1 mM Sodium Pyruvate (Gibco), and, for Mel375iDUX4 and Mel526iDUX4, 2 μ g/ml or 1 μ g/ml puromycin, respectively. SuSa and SuSaiDUX4 cells were maintained in RPMI 1640 Medium supplemented with 10% HyClone Fetal Bovine Serum, 100 U/100 μ g penicillin/streptomycin, and, for SuSaiDUX4, 1 μ g/ml puromycin. A204iDUX4, HeLaiDUX4, MCF-7iDUX4, Mel375iDUX4, Mel526iDUX4, SuSaiDUX4, and MB135iDUXB cell lines were generated as previously described for MB135iDUX4 cells (Jagannathan et al., 2016).

METHOD DETAILS

Data Sources

RNA-seq reads were downloaded from CGHub (TCGA), the Gene Expression Omnibus (accession numbers GSE85632, GSE85935, GSE78220) (Eidahl et al., 2016; Hendrickson et al., 2017; Hugo et al., 2016), the NCBI sequence read archive (SRA) database (accession number SRP058319) (Rickard et al., 2015), dbGaP (accession number phs000452.v2.p1) (Van Allen et al., 2015), the Japanese

Genotype-Phenotype Archive (accession number JGAS00000000047) (Yasuda et al., 2016), and the European Genome-phenome Archive (accession number EGAD00001002112) (Lilljebjörn et al., 2016). Sample annotations and gene expression data were downloaded from the GTEx portal (www.gtexportal.org). ChIP-seq reads were downloaded from the Gene Expression Omnibus (accession number GSE33838) (Geng et al., 2012).

RNA-seq Library Preparation

Total RNA integrity was checked using a 4200 TapeStation System (Agilent Technologies) and quantified using a Trinean DropSense 96 UV-Vis spectrophotometer (Caliper Life Sciences). The RNA-seq libraries were prepared from total RNA using the TruSeq RNA Sample Prep Kit v2 (Illumina). Library size distribution was validated using a 4200 TapeStation System. Additional library quality control, blending of pooled indexed libraries, and cluster optimization was performed using a Qubit 2.0 Fluorometer (Life Technologies-Invitrogen). RNA-seq libraries were pooled (16-plex) and clustered onto 2 flow cell lanes. Sequencing was performed using an Illumina HiSeq 2500 in high-output mode employing a single-end, 100 base read length sequencing strategy. All work was carried out by the Fred Hutch Genomics Shared Resource.

Genome annotation, RNA-seq and ChIP-seq Read Mapping, and Gene Expression Estimation

A genome annotation was created by merging the UCSC knownGene (Meyer et al., 2013), Ensembl 71 (Flicek et al., 2013), and MISO v2.0 (Katz et al., 2010) annotations. RNA-seq reads were mapped to this annotation as previously described (Dvinge et al., 2014). In brief, RSEM v1.2.4 (Li and Dewey, 2011) was modified to call Bowtie v1.0.0 (Langmead et al., 2009) with the option '-v 2' and then used to map all reads to the merged genome annotation. Remaining unaligned reads were then mapped to the genome (GRCh37/hg19 assembly) and a database of potential splice junctions with TopHat v2.0.8b (Trapnell et al., 2009). All gene expression estimates were normalized using the trimmed mean of M values (TMM) method (Robinson and Oshlack, 2010). For GTEx data, per-tissue gene expression estimates were obtained by computing the median expression over all samples for a given tissue following TMM normalization. Read alignments to the full-length DUX4 cDNA were performed with Kallisto v0.43.0's pseudoalignment function (Bray et al., 2016). Subsequent visualization of the resulting read coverage was performed with IGV (Thorvaldsdottir et al., 2013). ChIP-seq reads were mapped to the genome with Bowtie v1.0.0 (Langmead et al., 2009) with the arguments '-v 2 -k 1 -m 1 -best -strata'. ChIP-seq peaks were called with MACS v 2.1.1.20160309 (Zhang et al., 2008) with the arguments 'callpeak -g hs'.

Cancer-Specific Expression Score

The cancer-specific expression score of each gene was defined as the logarithm of the fractions of cancer samples and types in which the gene was expressed divided by the fractions of peritumoral samples and normal tissues in which the gene was expressed. We used the following thresholds to define a gene as expressed or not expression in a given sample. Following TMM normalization, each gene within each sample was classified as expressed (>1.5 TPM), not expressed (<0.5 TPM in normal tissue), or uncertain (<1.5 TPM, but >0.5 TPM). For peritumoral samples, we relaxed the threshold for defining genes as not expressed to <1.0 TPM in order to allow for potential cancer field effects, sample contamination, or other confounding factors. We defined DUX4+ and DUX4- cancer samples as those with DUX4 expression >1.5 TPM or <0.5 TPM.

DUX4 Polyadenylation Site Usage

The alleles from which DUX4 mRNAs were expressed in a sample were determined from diagnostic polymorphisms in exon 2 of DUX4 (Snider et al., 2010). This information was inferred from the nucleotide sequences at genomic positions chrUn_gi000228:114,025-114,056 in mapped RNA-seq reads, corresponding to the sequences shown in Table 4 of Snider et al. (2010). Mapped RNA-seq reads containing the DUX4 exon 3 polyadenylation sites were defined as reads that overlapped the ATATATAAA sequence at chrUn_gi000228:114,642-114,651 with no mismatches.

Somatic Mutation Analysis

TCGA somatic mutation calls from the Mutect pipeline (Cibulskis et al., 2013), together with their phenotypic impact as predicted by PolyPhen (Adzhubei et al., 2010) were obtained using the GDCquery_Maf function from TCGAbiolinks (Colaprico et al., 2016). Mutations were segregated as deleterious (frameshift, nonsense, and predicted deleterious mutations), low impact (silent and predicted tolerated) or other. In each cancer cohort, for each gene tested, samples with deleterious mutations were compared to samples with low impact or no mutations.

DUX4 and DUX4C Comparison

RNA-seq reads that mapped uniquely to full-length DUX4 mRNA or DUX4C mRNA were extracted using samtools view (Li et al., 2009) with the following coordinates in the GRCh37/hg19 assembly: DUX4, chrUn_gi000228:113631-113879; DUX4C, chr4:190942696-190942795 and chrUn_gi000228:26525-26624 (those two loci have identical genomic sequences). The density of reads was calculated as the total number of reads mapping to the region, normalized by the lengths of the regions queried.

DUX4 and DUX4-s Isoform Comparison

Uniquely identifying splice junctions for the long and short isoforms of DUX4 mRNA were identified by their 5' splice sites at chrUn_gl000228:113,887 and chrUn_gl000228:113,081, respectively.

DUXB Differential Gene Expression Analysis

DUXB target genes were defined as those genes that were expressed at >5 TPM following DUXB induction, exhibited a fold-change >2 relative to uninduced samples, and had an associated Bayes factor of >10 as computed with Wagenmakers's framework (Wagenmakers et al., 2010) in both experimental replicates.

DUX4 Differential Gene Expression Analysis

A high-confidence set of DUX4 target genes were defined as expressed at >5 TPM in DUX4+ samples, with a greater than 4-fold change over DUX4- samples, and with a Bayes factor of >10 as computed with Wagenmakers's framework (Wagenmakers et al., 2010) in all experimental replicates, across samples from pre-implantation embryos (Hendrickson et al., 2017), myoblasts (Feng et al., 2015) and iPSCs (Hendrickson et al., 2017).

Differential Gene Expression and Gene Ontology Analyses

Genes that were differentially expressed in DUX4+ versus DUX4- cancer samples were determined with a two-sided Mann-Whitney test, as implemented in `wilcox.test` in R, with a p value threshold of 0.01 and a fold-change threshold of 2.0. Gene Ontology (GO) terms that were enriched amongst genes that exhibited increased or decreased expression in DUX4+ versus DUX4- samples were identified with the GOrse method (Young et al., 2010), with a false-discovery rate threshold of 0.01. The intersection between the resulting significant GO terms that were identified for each cancer type was then computed, and only the child-most terms of the resulting intersection were analyzed further and reported.

Quantification of Immune Cell Infiltration

Estimates of immune cell infiltration of TCGA primary tumors were downloaded from the TIMER web server (Li et al., 2017) and cross-referenced to our classification of each sample as DUX4+ or DUX4-. A one-sided Mann-Whitney U test was used to test for a statistically significant difference in immune cell infiltration between DUX4- and DUX4+ cancer samples.

Cloning

The *DUXB* gene was codon altered, synthesized by IDT custom gene synthesis, and subcloned by restriction enzyme digest into the *NheI* and *Sall* sites of the pCW57.1 vector, a gift from David Root (Addgene plasmid #41393).

siRNA Transfection

FlexiTube GeneSolution siRNAs targeting *PRPF8* (Cat. no. GS10594) and a non-targeting Negative Control siRNA (Cat. no. 1022076) were obtained from Qiagen. Transfection of siRNAs into myoblasts was carried out as previously described (Campbell et al., 2018).

MHC Class I Immunoblotting and Induction by Interferon- γ

Cells were treated with 1 μ g/ml doxycycline hyclate (Sigma-Aldrich) for 4 h and then stimulated with 100-200 ng/ml interferon- γ (R&D Systems) for 14-17 h. Whole-cell protein extracts were obtained by lysing cells directly in 4X SDS sample buffer (500 mM Tris-HCl pH 6.8, 8% SDS, 20% 2-mercaptoethanol, 0.004% bromophenol blue, 30% glycerol) or RIPA buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 25 mM Tris-HCl pH 7.4), followed by sonication. Protein extracts were run on NuPAGE 4-12% precast polyacrylamide gels (Invitrogen) and transferred to nitrocellulose membrane (Invitrogen). Membranes were blocked in PBS containing 0.1% Tween-20 and 5% non-fat dry milk before overnight incubation at 4 °C with primary antibodies. Membranes were then incubated with horseradish peroxidase-conjugated secondary antibodies in block solution for 1 h at room temperature and chemiluminescent substrate (Thermo Fisher Scientific) was used for detection on film or with a ChemiDox MP Imaging System (Bio-Rad). Membranes were stripped with Restore Western Blot Stripping Buffer (Pierce) before being re-probed.

Real-Time qPCR

Total RNA was extracted from whole cells using the NucleoSpin RNA kit (Machery-Nagel) according to the manufacturer's instructions. Isolated RNA was treated with DNase I (Thermo Fisher Scientific), heat inactivated, and reverse transcribed into cDNA using SuperScript III (Thermo Fisher Scientific) and oligo(dT) primers (Invitrogen) following the manufacturer's protocol. Quantitative PCR was carried out on a QuantStudio 7 Flex (Applied Biosystems) using primers specific for each mRNA and iTaq SYBR Green Supermix (Bio-Rad Laboratories). The relative expression levels of target genes were normalized to that of reference housekeeping genes by using the delta-delta-Ct method (Livak and Schmittgen, 2001) after confirming equivalent amplification efficiencies of reference and target molecules.

Flow Cytometry

Cells were treated with 1 μ g/ml doxycycline hyclate (Sigma-Aldrich) for 4 h and then stimulated with 200 ng/ml interferon- γ (R&D Systems) for 16 h. Cells were harvested using trypsin, washed with FACS Buffer (1X DPBS, 2% FBS), and then stained with a

1:50 dilution of FITC-conjugated MHC class I antibody (Biolegend) for 30 min at 4°C. Following staining, cells were washed again and resuspended in FACS buffer for analysis by flow cytometry using BD LSRFortessa X-50 with BD FACSDiva software (BD Biosciences). Data were analyzed using FlowJo v10.5.3.

Antibodies

The following antibodies were used: GAPDH (6C5) (GeneTex GTX28245; Lot #23184, Lot #821705388, or Lot #821803139), MHC class I (F-3) (Santa Cruz Biotechnology sc-55582; Lot #C0817 or Lot #L1118), FITC anti-human HLA-A,B,C (W6/32) (BioLegend 311404; Lot #B223038), ZSCAN4 (Invitrogen PA5-32106; Lot #SK2479411A), Peroxidase AffiniPure Goat Anti-Mouse IgG (H+L) (Jackson ImmunoResearch 115-035-146), and Peroxidase AffiniPure Goat Anti-Rabbit (H+L) (Jackson ImmunoResearch 111-035-144), and a previously described rabbit monoclonal antibody against DUX4 (E14-3) that was produced in collaboration with Epitomics (Geng et al., 2011).

Primers

The following primers were used:

B2M F: ACTGAATTCACCCCCACTGA (Zhang et al., 2005)
 B2M R: CCTCCATGATGCTGCTTACA
 CXCL9 F: TCTTTTCCTCTTGGGCATCA (Zeisel et al., 2013)
 CXCL9 R: TAGTCCCTTGGTTGGTGCTG
 CXCL10 F: GTGGCATTCAAGGAGTACCTC (Wang et al., 2012)
 CXCL10 R: TGATGGCCTTCGATTCTGGATT
 DUX4 F: CGGAGAACTGCCATTCTTTC (Shadle et al., 2017)
 DUX4 R: CAGCCAGAATTCACGGAAG
 HLA-A F: CGACGCCGCGAGCCAGA (Kruse et al., 2015)
 HLA-A R: GCGATGTAATCCTTGCCGTCGTAG
 HLA-B F: CTACCCTGCGGAGATCA (Meissner et al., 2010)
 HLA-B R: ACAGCCAGGCCAGCAACA
 HLA-C F: GGAGACACAGAAGTACAAGCG (Kruse et al., 2015)
 HLA-C R: CGTCGTAGGCGTACTGGTCATA
 PRPF8 F: ACCCAATCTCCCATAGGCAC (Zeisel et al., 2013)
 PRPF8 R: AGGAAGGGCTCCACAACTC
 RPL13A F: AACCTCCTCCTTTTCCAAGC (Geng et al., 2012)
 RPL13A R: GCAGTACCTGTTTAGCCACGA
 RPL27 F: GCAAGAAGAAGATCGCCAAG (Shadle et al., 2017)
 RPL27 R: TCCAAGGGGATATCCACAGA
 TRIM43 F: ACCCATCACTGGACTGGTGT (Geng et al., 2012)
 TRIM43 R: CACATCCTCAAAGAGCCTGA
 ZSCAN4 F: TGGAAATCAAGTGGCAAAA (Geng et al., 2012)
 ZSCAN4 R: CTGCATGTGGACGTGGAC

siRNAs

The following siRNAs were used:

siCTRL: AATTCTCCGAACGTGTCACGT
 siPRPF8-1: ACGGGCATGTATCGATACAAA
 siPRPF8-2: ATGGCTTGTCATCCTGAATAA
 siPRPF8-3: CAACGTCGTCATCAACTATAA
 siPRPF8-4: CTCATCGTGGACCACAACATA

Survival analyses

Survival analyses and corresponding statistical tests were performed with the Kaplan-Meier estimator and log-rank test as implemented in the R package survival (Therneau and Grambsch, 2000).

QUANTIFICATION AND STATISTICAL ANALYSIS

Data Analysis and Visualization

Data analysis was performed in the R programming environment and relied on Bioconductor (Huber et al., 2015), CRAN: dplyr (Wickham et al., 2018), and CRAN: ggplot2 (Wickham, 2016). The RT-qPCR panels were generated using GraphPad Prism Software (version 7.0, www.graphpad.com). Flow cytometry data were analyzed with FloJo (version 10.5.3, www.flowjo.com/solutions/flowjo).

DATA AND CODE AVAILABILITY

Experimental Data and Plasmids

Relevant plasmids are available through Addgene (https://www.addgene.org/Stephen_Tapscott/).

Accession Codes

The accession number for the FASTQ files from the DUXB RNA-seq experiment reported in this paper is GSE128917.